The week in health deals and policy: Medicare Advantage plans face audits and ratings overhaul
CMS proposed a fraud rule and a Star Ratings rewrite that both reach Medicare Advantage insurers. In the same week, J&J, Lilly and private investors put billions into drug programs that have no late-stage data.

This week's largest drug deals went to programs still years from market, and the two largest federal proposals both reached Medicare Advantage insurers. Between Nov. 16 and Nov. 20, Johnson & Johnson and Eli Lilly agreed to buy young biotechs, Isomorphic Labs raised $5 billion, and the Centers for Medicare & Medicaid Services proposed an anti-fraud rule and an overhaul of MA Star Ratings.
Why it matters: Buyers and private investors put billions into programs that have no late-stage data, and in one deal an outside investor was lined up to pay for Phase 3. MA plans face proposals that CMS says would recover billions in coding overpayments and raise the bar for top ratings, while also lowering a barrier for new competitors.
The money went to early science
J&J agreed to pay $2.2 billion upfront for Ollin Biosciences, plus up to about $1.125 billion in milestones, for an eye disease antibody that J&J describes as a Phase 3 candidate. Blackstone Life Sciences agreed to pay J&J $750 million over several years toward the Phase 3 program, contingent on the deal closing, J&J said.
Lilly agreed to pay up to $1.5 billion for Calytrix Bio, a company founded in 2025 whose blood cancer antibody has not yet been tested in humans. Because the upfront amount was not disclosed, the $1.5 billion figure is a maximum rather than the closing payment.
Venture investors followed the same pattern. Isomorphic Labs, which uses AI to design drugs, raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital. That came six months after a $2.1 billion Series B, UKTN reported, and the company has not said when a first candidate will enter human testing. Marrow Therapeutics launched with $173 million from two rounds while its lead program is still in IND-enabling studies.
Device financing favored companies closer to revenue. Galvanize Therapeutics raised a $130 million Series D to grow sales of Aliya, which is 510(k)-cleared. Galvanize's Form D, filed Nov. 18, lists $136M sold, according to SEC Form D filings. Remedy Robotics raised $62 million to pay for a pivotal trial of its endovascular robot.
Across the sector, 114 health-care companies reported $1.4B in sales on new Form D filings over the past 30 days, according to SEC Form D filings.
CMS tightens and loosens Medicare Advantage at once
CMS's CRUSH proposed rule would write into regulation the extrapolation of risk adjustment audit findings beginning with payment year 2018. CMS estimates that piece alone would recover about $9 billion per payment year on average, and puts savings for the whole package at nearly $90 billion from 2027 through 2036. Plans would also have to report suspected fraud, and clinicians who bill MA plans would have to enroll in Original Medicare. Comments are due Jan. 19, 2027.
Four days later, CMS's Medicare Advantage proposed rule would narrow Star Ratings to 15 measures. CMS said its method changes would make top ratings, and the bonus payments linked to them, harder to reach. The same proposal would let new plans demonstrate network adequacy during their first year rather than at application, which CMS said would ease entry into new markets. It also introduces ADVaNCE MA, a mandatory 10-year model starting in 2029 in states CMS has not yet identified.
Enrollment rules for providers tightened as well. CMS extended its moratoriums on new Medicare hospices and home health agencies for six months, while allowing operators already enrolled to open new locations again. Separately, CMS said accountable care organizations in the Medicare Shared Savings Program earned a record $4.9 billion for 2025, even as Medicare's net savings per beneficiary fell to $234 from $241 with more ACOs in two-sided risk.
HHS also finalized a HIPAA Privacy Rule that shortens the deadline for answering patient record requests to 15 days from 30 and prohibits fees for portal and app access. HHS estimates first-year compliance costs at $783.98 million.
What to watch
J&J expects the Ollin deal to close before the end of 2026, and Rosemont Pharmaceuticals expects its roughly $56 million tender offer for Aytu BioPharma to close in late December. On policy, the markers are the Jan. 19 CRUSH comment deadline, the 60-day comment period on the MA rule after Federal Register publication, and the HIPAA rule, which takes effect 60 days after its scheduled Nov. 19 publication. Still unanswered: which states CMS selects for ADVaNCE MA, which 15 measures remain in the ratings, and when Lilly, Isomorphic and Marrow begin human studies.


